REG - Fusion Antibodies - Antibody IP transfer agreement

Fusion AntibodiesAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd5357Ya&default-theme=true

RNS Number : 5357Y  Fusion Antibodies PLC  30 March 2026

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse (amendment)
(EU Exit) Regulations 2019/310 ("MAR"). With the publication of this
announcement via a Regulatory Information Service, this inside information is
now considered to be in the public domain.

 

30 March 2026

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Antibody IP transfer agreement

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that it has entered into an agreement to transfer the
ownership of certain background intellectual property ("IP") owned by Fusion
(the "IP Transfer Agreement") to an existing client, Finn Therapeutics Ltd
(the "Client"). The IP Transfer Agreement covers a novel rabbit antibody.

 

The IP Transfer Agreement results in a one-off payment to Fusion of £250,000
for the IP and related reach through to the humanized sequences. The Client is
pleased to take ownership of the background IP as this is expected to
streamline its fundraising activities and the Company has agreed to tailored
payment terms with the Client to allow for these fundraising activities.

 

The Client has been working closely with Fusion, placing a series of projects
with the Company and has indicated it intends to continue to do so as the
development of the humanised antibody progresses. The entire IP Transfer
Agreement fee payable to Fusion will be recognised in the current financial
year ending 31 March 2026.

 

Adrian Kinkaid, CEO of Fusion, said: "We are delighted with the progress that
has been made with this molecule and its derivatives. We recognise the
challenging investment conditions many small biotechnology companies face at
this time and are keen to support our clients with creative deal solutions
such as this. We look forward to working with Finn Therapeutics as they
progress this project and bring better antibodies to the clinic more rapidly.
The project highlights the strong reputation that Fusion has as the
collaborative research partner of choice for antibody therapeutics."

 

Paul Kerr, CEO of Finn Therapeutics commented: "Acquiring full ownership of
this background IP is a significant de-risking event that streamlines our
fundraising and accelerates our path to clinical entry. As an asset-centric
company; this move allows us to efficiently leverage our development partners
and we look forward to continuing our relationship with Fusion, as we work to
redefine the standard of care with this first-in-class oncology candidate."

 

Navigate to our Interactive Investor hub here:
https://investorhub.fusionantibodies.com/
(https://investorhub.fusionantibodies.com/) . Engage with us by asking
questions, watching video summaries and seeing what other shareholders have to
say.

 

Enquiries:

 

 Fusion Antibodies plc                                                             www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Fusion Antibodies interactive investor hub                             https://investorhub.fusionantibodies.com/
                                                                        (https://investorhub.fusionantibodies.com/)

 Allenby Capital Limited                                                Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                             Tel: +44 (0) 207 186 9952

 Walbrook PR                                 Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                                         Mob: +44 (0)7876 741
                                                                        001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRPPUWPWUPQGUB



            Copyright 2019 Regulatory News Service, all rights reserved